Case for caution in expanding attention deficit hyperactivity disorder prescribing

Expanding psychostimulant prescribing to general practitioners (GPs) addresses Australia's attention deficit hyperactivity disorder (ADHD) access crisis, but risks significant unintended consequences. This article highlights the cumulative risks of long-term stimulant use and the danger of fragmented care models. We argue that inconsistent training and the rise of vertically integrated telehealth platforms threaten to reduce ADHD care to a volume-based pharmacological service. To protect public health, Australia requires a national framework prioritising mandatory education, shared care pathways and periodic reviews. Success must be measured by the quality of holistic care, not merely script volume.